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Background: Previous studies have provided equivocal data on the use of miglustat as maintenance therapy in
Gaucher disease type 1. We report findings from a clinical trial evaluating the effects of miglustat treatment in
patients with stable type 1 Gaucher disease after enzyme therapy.
Methods: Adult type 1 Gaucher disease patients stabilized during at least 3 years of previous enzyme therapy were
included in this 2-year, prospective, open-label non-inferiority study. The primary endpoint was percent change
from baseline in liver volume. Secondary endpoints included changes in spleen volume, hemoglobin concentration
and platelet count.
Results: Forty-two patients were enrolled (mean±SD age, 45.1±12.7 years; previous enzyme therapy duration
9.5±4.0 years). Median (range) exposure to miglustat 100 mg t.i.d. was 658 (3–765) days. Twenty-one patients
discontinued treatment prematurely; 13 due to adverse events, principally gastrointestinal. The upper 95%
confidence limit of mean percent change in liver volume from baseline to end of treatment was below the
non-inferiority margin of 10% (–1.1%; 95%CI −6.0, 3.9%). Mean (95%CI) changes in spleen volume, hemoglobin
concentration and platelet count were 102 (24,180) mL, –0.95 (−1.38, –0.53) g/dL and −44.1
(–57.6, –30.7) ×109/L, respectively.
Conclusions: The primary efficacy endpoint was met; overall there was no change in liver volume during 24
months of miglustat therapy. Several patients showed a gradual deterioration in some disease manifestations,
suggesting that miglustat could maintain clinical stability, but not in all patients. Miglustat demonstrated a
predictable profile of safety and tolerability that was consistent with that reported in previous clinical trials and
experience in clinical practice.
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Type 1 Gaucher disease is an inherited lysosomal disorder
caused by impaired activity of β-glucocerebrosidase,
and xaccumulation of glucosylceramide in pathologic
macrophages in the liver, spleen, bone marrow and, less
frequently, the lungs [1,2]. The most common clinical
variant is type 1 Gaucher disease, which is characterized
by anemia, thrombocytopenia, hepatosplenomegaly and
skeletal manifestations such as bone pain, osteopenia,
fragility fractures and osteonecrosis [2-5].
Enzyme therapy (often mistakenly termed enzyme
replacement therapy) with recombinant human β-
glucocerebrosidase (imiglucerase [CerezymeW], Gen-
zyme Therapeutics; velaglucerase [VPRIV™], Shire plc)
reduces organomegaly and improves hematologic and
biochemical parameters in type 1 Gaucher disease
[6,7]. However, enzyme therapy requires regular intra-
venous infusions, which are a lifestyle burden for some
patients [8,9].
Miglustat (ZavescaW; Actelion Pharmaceuticals) is an
orally active iminosugar which reversibly inhibits UDP-
glucosylceramide synthase – the enzyme that catalyzes
the rate-limiting step in glycosphingolipid biosynthesis.
Miglustat was approved in Europe in 2002 and in the
USA in 2003 for use as a substrate reduction therapy in
adult patients with mild-to-moderate type 1 Gaucher
disease for whom enzyme therapy is unsuitable or not a
therapeutic option [10,11].
During developmental clinical trials, miglustat induced
sustained reductions of liver and spleen volumes, with
increased hemoglobin concentrations and platelet counts;
the plasma activity of the biomarker, chitotriosidase, also
decreased [12-15]. Similar effects have been observed in
‘real-world’ clinical practice settings [16,17]. It has also
been suggested that miglustat improves cortical and
trabecular bone mineral density (BMD) during 6 months
to 2 years of therapy, and can reduce the frequency of
bone pain in a sustained manner [18].
A randomized, open-label Phase II clinical trial evalu-
ated the use of miglustat, given alone or in combination
with enzyme therapy, in type 1 Gaucher disease patients
stabilized by long-term treatment with imiglucerase [19].
However, equivocal beneficial effects on the disease,
observed over a limited duration of assessment in a
small number of patients, did not allow a definitive con-
clusion as to whether oral miglustat is effective in main-
taining clinical stability in patients with type 1 Gaucher
disease after they have received enzyme therapy. Further
clinical trial data were requested by the European
Medicines Association (EMA) to investigate this issue
more fully, and a suitable study design was defined
through subsequent consultation.
Here we report the findings of a study of miglustat as
maintenance treatment in adult patients whose type 1Gaucher disease had been controlled by enzyme therapy.
As the inclusion of a placebo or non-drug arm was
considered unethical for this patient population, the
study was of an open-label, non-controlled design.
Methods
Study design and patients
This was a multicenter, international, open-label, Phase
IIIb non-inferiority study comprising a 6-month screen-
ing period, a 24-month treatment period and a 28-day
safety follow-up period. The primary objective was to
evaluate the long-term effect of miglustat maintenance
therapy on liver volume in adult patients with stable
type 1 Gaucher disease who switched to miglustat
from enzyme therapy. The secondary objectives were to
examine the effects of miglustat on spleen volume and
other type 1 Gaucher disease manifestations during
long-term maintenance therapy. The safety and tolera-
bility of miglustat was also assessed, including neurological
and neuropsychological assessments.
Male and female patients aged at least 18 years with
confirmed, stable type 1 Gaucher disease, who had
undergone 3 or more years of enzyme therapy and had
been on a stable enzyme dose for at least 6 months were
included. Patients were required to have stable disease
for 2 or more years before enrolment, defined by assess-
ments during at least two appropriate time points con-
firming the following: stable organomegaly, with the last
three liver and spleen volume assessments within 10%
of the mean of these values (as assessed by magnetic res-
onance imaging [MRI] or computed X-ray tomography
[CT]); a documented absence of symptomatic bone dis-
ease; mean hemoglobin level >11 g/dL; mean platelet
count >100 × 109/L; stable chitotriosidase activity, with
the last three values within 20% of these values.
The stability of disease in individual study participants
was adjudicated at the beginning of the study by an
independent Steering Committee comprising five clinical
experts in Gaucher disease who were neither investigators
nor directly involved in the conduct of the study. This
Steering Committee also adjudicated cases of suspected
disease worsening during the study, and carried out a final
adjudication of all referred cases at the end of the study.
Patients were excluded if they had manifestations of
neuronopathic Gaucher disease, were non-ambulatory or
had symptomatic bone disease. Other reasons for exclu-
sion included splenectomy before 18 years of age, docu-
mented peripheral polyneuropathy comprising suggestive
symptoms, compatible clinical signs and electrodiagnosis,
a history of lactose intolerance, diarrhea (>3 liquid stools
per day for >7 days), or a history of gastrointestinal
disorders.
All patients provided written informed consent for
study entry. The protocol and management structure
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Boards or Independent Ethics Committees, and the
study was conducted in accordance with the principles
and procedures outlined in the Declaration of Helsinki.
This trial was registered on www.clinicaltrials.gov on
April 26, 2006 (identifier # NCT00319046).
Treatment
All patients were prescribed oral miglustat 100 mg capsules
three times daily throughout the 24-month treatment
period, as specified in the prescribing information [11].
Dose reduction to 100 mg once or twice a day was permit-
ted if patients experienced treatment-related diarrhea or
other gastrointestinal symptoms, and this reduction was
maintained until the symptoms subsided.
Efficacy endpoints
The primary efficacy endpoint was the mean percent
change in liver volume from baseline to Month 24. Liver
volume was assessed by MRI every 6 months. Mean
change in spleen volume from baseline to Month 24 was
determined as a secondary efficacy endpoint. Spleen and
liver volume were measured centrally by a specialized
imaging center (SYNARC, Sèvres, France), as well as lo-
cally at each study center. Hemoglobin concentration
and platelet count were also assessed locally during each
clinic visit as secondary efficacy endpoints. The disease
biomarker, chitotriosidase activity, was measured at a
central laboratory in plasma samples obtained at all vis-
its during the treatment period.
Mean change in the bone marrow burden (BMB) score
from baseline to Month 24 was measured as a secondary
efficacy endpoint based on the sum of scores from stan-
dardized semi-quantitative MRI-based assessments of
bone marrow infiltration in axial (lumbar spine) and per-
ipheral (femoral) sites at baseline, Month 12 and Month
24. Scores from 1 to 8 were assigned at each skeletal site,
giving a maximum total of 16; higher scores represent
more severe bone marrow infiltration. BMB scores were
assessed locally at each study center (when possible), as well
as centrally by a specialized imaging center (SYNARC)
using published methods [20].
The proportion of patients that worsened was also
determined. If investigators suspected disease worsening,
the Steering Committee was asked to adjudicate as to
whether, on the basis of the available clinical data, the
patient had worsening of their disease. The following
pre-defined criteria were taken as potential signals of
disease worsening: increase in liver volume ≥10% from
baseline; increase in spleen volume ≥10% from baseline;
hemoglobin concentration decreased ≥1 g/dL from base-
line; reduction in platelet count at two consecutive la-
boratory evaluations (according to pre-defined criteria);
any clinical signs or symptoms (e.g. documented bonecrisis) or change in relevant biomarkers (e.g. increase in
chitotriosidase activity or changes in serum ferritin, ACE
or TRAP) that suggested disease worsening in the inves-
tigator’s opinion. Confirmation of disease worsening by
the Steering Committee required consistent clinical and
biological documentation so that an isolated signal may
not have been considered sufficient to confirm disease
worsening; agreement in each case was reached by
consensus.
When disease worsening was confirmed by the Steering
Committee, miglustat was discontinued and enzyme
therapy was reintroduced at a dose considered most ap-
propriate by the investigator. Patients who discontinued
treatment before Month 24 were allowed to remain in the
study and underwent the remaining assessments. In cases
of ‘suspected disease worsening’, where worsening of a
patient’s disease was suspected by the Steering Committee
but not confirmed by further clinical evaluation, additional
information and/or assessments were requested. Under
these circumstances, miglustat was continued until a final
decision was reached. In cases where worsening of the dis-
ease was suspected by the investigator but not confirmed
by the Steering Committee, treatment with miglustat
could be continued until Month 24. A final adjudication
on disease worsening based on all available data (including
central laboratory imaging findings) was carried out at the
end of the study, and the reported numbers of patients
with clinical worsening is based on this final adjudication.
Additional analysis: maintenance of therapeutic goals
An additional analysis of the achievement of accepted
type 1 Gaucher disease therapeutic goals in patients who
completed 24 months of miglustat treatment was also
conducted. While not defined a priori, this analysis did
not formally constitute a post-hoc analysis as it was
included in the statistical analysis plan before database
closure. Therapeutic goals were defined as previously
described [21].
Safety and tolerability
Treatment-emergent adverse events (i.e. all adverse
events occurring in enrolled patients who received at
least one dose of study medication) and serious adverse
events were recorded throughout the study. Standard la-
boratory measurements including hemoglobin, platelet
counts, biochemistry (including vitamins B12 and B1),
and serum protein electrophoresis were examined in
blood samples taken at each clinic visit.
Rigorous testing for peripheral neuropathy was per-
formed in all patients by a trained, certified neurologist at
each clinical site based on patients’ medical history and
assessments of clinical signs and symptoms, as described
previously [4]. All patients also underwent electrodiagnos-
tic assessments at baseline, including nerve conduction
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presented new or aggravated clinical signs and/or symp-
toms that suggested possible peripheral neuropathy during
the study, a repeat electrodiagnostic examination was
carried out by the local neurologist to confirm the diagno-
sis. At the end of the study, electrodiagnostic data were
evaluated centrally by an independent assessor. Diagnoses
of peripheral neuropathy were assigned on the basis of
compatible clinical signs and/or symptoms accompanied
by compatible electrodiagnostic findings.
Neuropsychological assessments of cognitive function
were also conducted by qualified personnel at baseline
and every 6 months throughout the study. These com-
prised a battery of tasks derived from the CDR compu-
terized cognitive assessment system, and assessed the
following cognitive domains: simple reaction time; digit
vigilance; choice reaction time; spatial working memory;
numeric working memory; word recognition; picture
recognition; Morse tapping [25,26]. Alertness and self-
rated mood were also each evaluated using Bond-Lader
visual analogue scales [27].
Statistical analysis
A sample size of 42 patients was agreed as appropriate
to meet the objectives of the study with the European
Medicines Agency (EMA) Committee for Medicinal
Products for Human Use (CHMP). Relevant study popu-
lations were defined as follows: ‘all-enrolled population’
- all enrolled patients regardless of whether they
received study drug; ‘full analysis population’ - all en-
rolled patients who received study drug and had ≥1
post-baseline value for the primary endpoint; ‘per proto-
col population’ - patients in the full analysis population
who completed the 24-month treatment period and did
not have major protocol deviations that might have
affected the primary endpoint.
Based on the standard deviation (SD) of the percent
change in liver volume during a previous randomized
clinical trial with miglustat (9.2%) [19], a clinically rele-
vant non-inferiority limit of a 10% increase in liver
volume was selected for the primary endpoint of this
study. The null hypothesis was that the mean change in
liver volume from baseline to Month 24 was ≥10%. The
alternative hypothesis was that there was no change in
liver volume. The null hypothesis was rejected if the
upper limit of the two-sided 95% confidence interval
(CI) around the mean change in liver volume from base-
line to Month 24 was <10%.
Mean percent change in liver volume was determined
by analyzing all available liver volume data from the full
analysis population using a one-sample t-test with no
adjustments for covariates. For the 20 patients in the full
analysis population who discontinued miglustat prema-
turely, the worst (greatest) post-baseline value for livervolume on treatment was carried forward to substitute
the Month 24 value in an ‘end of treatment’ analysis.
A sensitivity analysis was performed by comparing
results from the full analysis population with the same
analyses applied to the per-protocol population.
No formal statistical testing was carried out for
secondary efficacy endpoints (change in spleen volume,
hemoglobin concentration and platelet count), as there
was no hypothesis test defined a priori for any of these
endpoints, which are hypothesis-generating as opposed
to inferential. Absolute values at baseline and follow up,
and change from baseline data were summarized from
the full analysis population using mean, SD and 95% CI.
Descriptive ‘end of treatment’ analyses were conducted
using last observations carried forward to impute miss-
ing values from patients who discontinued miglustat
prematurely. Changes in hematological parameters and
organ volumes were compared to previously defined
therapeutic goals for Gaucher disease (21). These goals
have not been validated but they may serve as bench-
marks for clinically important changes.
Results
Patients
Forty-two patients (22 male, 20 female) were enrolled from
21 February 2006 onwards from 16 centers in Australia,
Brazil, Canada, Czech Republic, France, Netherlands, Spain,
Taiwan, UK, and the USA. The trial ended on 22 June
2010. The mean (SD) age at enrolment was 45.1 (12.7)
years, and age at diagnosis was 24.8 (15.0) years (Table 1).
Patients had previously received enzyme therapy for an
average of 9.5 years, and had received the same dose of
enzyme therapy (median [range] 54.7 [5.2–130.7] IU/kg/
month) for approximately 5 years.
Patients in the ‘all enrolled’ patient population displayed
relatively mild disease at baseline, with normal mean (SD)
liver volume (0.91 [0.22] multiples of normal [15]), only
mild splenomegaly among non-splenectomized patients
(3.13 [1.76] multiples of normal [15]), and normal
hemoglobin concentrations and platelet counts (Table 1).
Overall, 80% of patients had attained the therapeutic goals
at baseline [28]. Most patients (33/42; 78.6%) had intact
spleens.
All 42 enrolled patients received ≥1 dose of the study
drug (‘all-enrolled population’) and 41 patients had ≥1
post-baseline assessment for the primary endpoint (full
analysis population) (Figure 1). There were a total of 21
premature discontinuations from therapy during the
study, most of which were due to adverse events
(13 patients); one patient withdrew for administrative
reasons and one patient withdrew consent. Six patients
discontinued miglustat prematurely because of disease
worsening as assessed on the basis of local laboratory
and data.
Table 1 Patient demographics and characteristics at
baseline (all enrolled population)
All patients
(N = 42)
Demographics:
Age, years, mean ± SD 45.1 ± 12.7
Gender, male: female, n 22: 20
Body weight, kg, mean ± SD 76.7 ± 16.1
Height in cm, mean ± SD 169.9 ± 9.0
Race, n (%):
Caucasian 38 (90.5)
Asian 1 (2.4)
Hispanic 2 (4.8)
Other 1 (2.4)
Treatment history, mean ± SD:
Age at diagnosis, years 24.8 ± 15.0
Age at enzyme therapy initiation, years 35.6 ± 12.5
Duration of enzyme therapy, years 9.5 ± 4.0
Duration of current dose of enzyme therapy, years* 4.9 ± 2.8
Enzyme therapy dose at switch, IU/kg/month 61.3 ± 35.7
Disease parameters, mean ± SD:
Liver volume in mL (n = 40) 1726 ± 459.6
Liver volume in MN (n = 40) 0.91 ± 0.22
Spleen volume† in mL (n = 30) 484.7 ± 333.2
Spleen volume† in MN (n = 30) 3.13 ± 1.76
Hemoglobin, g/dL (n = 41) 14.89 ± 1.49
Platelet count, × 109/L (n = 41) 193.8 ± 92.06
*Median (range) dose of enzyme therapy 54.7 (5.2–130.7) IU/kg/month;
†excludes splenectomized patients; MN, multiples of normal.
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in the all-enrolled patient population was 658 (3–765)
days. Twenty-two of the 42 enrolled patients (52%) were
treated for ≥18 months. Overall, 21 patients completed
24 months of treatment, among whom 18 met criteria
for inclusion in the per protocol analysis. Patient charac-
teristics in the full analysis (n = 41) and per protocol
(n = 18) patient populations were comparable with those
in the entire study population.
Primary efficacy
Based on patients with available data in the full analysis
population (n = 32), the mean (95% CI) percent change
in centrally read liver volume from baseline to end of
treatment was −1.1% (−6.0% to 3.9%) (Table 2). As the
null hypothesis was rejected, the primary efficacy end-
point of the study was met – the upper limit of the two-
sided 95% CI was below the inferiority limit of 10%.
Sensitivity analysis showed consistent findings between
the full analysis population and per-protocol population
for liver volume (mean [95% CI] percent change +0.1%
[−7.4%, 7.5%]; n = 18). Mean absolute changes in livervolume from baseline were negligible during the course
of miglustat therapy (Figure 2A).
The primary efficacy endpoint was achieved in both
the splenectomized and non-splenectomized patient
subgroups (Table 2). Mean absolute liver volumes in
these subgroups remained below baseline throughout
treatment.
Secondary efficacy
Analyses in this section are based on available data for
the full analysis population. Mean absolute changes from
baseline in spleen volume, hemoglobin concentration
and platelet count up to Month 24 of miglustat therapy
are summarized in Figures 2B–D. Individual patient effi-
cacy findings are listed against gender and body weight
in Table 3.
Overall, spleen volume among the 22 evaluable, non-
splenectomized patients showed a mean (95% CI) increase
of 102 (24, 180) mL by Month 24 from a mean (SD) base-
line value of 510 (372) mL; the mean percent change by
Month 24 was 23% (95% CI: 7, 39). Changes from baseline
appeared maximal by Month 18.
There was a small mean (95% CI) decrease in
hemoglobin concentration of 0.95 (−1.38, −0.53) g/
dL at Month 24, from a mean (SD) baseline value of
14.8 (1.53) g/dL. The mean change from baseline
was maximal by Month 18, and the mean (SD)
hemoglobin concentration was 13.9 (1.55) g/dL at
end of treatment.
Platelet count showed a mean (95% CI) decrease of 44
(−58, −31) × 109/L from a mean (SD) baseline value of
199 (96) × 109/L. Again, maximal changes from baseline
were observed at Month 18. Baseline platelet counts
were higher in splenectomized patients (mean [SD] 304
[137] × 109/L) than in non-splenectomized patients
(mean [SD] 164 [38] × 109/L). Mean (95% CI) decreases
in platelet counts from baseline to Month 24 were also
greater in splenectomized patients (−66 [−111, −21] ×
109/L) compared with the non-splenectomized subgroup
(−37 [−48, −25] × 109/L). There were no reported epi-
sodes (adverse events) of bleeding or bruising in either
subgroup during miglustat therapy.
Sensitivity analysis demonstrated consistent findings
between the per-protocol population and the full ana-
lysis population for each key secondary endpoint.
Total BMB score evaluations from baseline to end of
treatment were available from 21 patients in the full ana-
lysis population (15 non-splenectomized and 6 splenec-
tomized). Overall, BMB scores showed a slight increase
(worsening) during the study; the median (95% CI) abso-
lute total BMB score increased from 5 (3, 7) at baseline
to 7 (4, 11) at the end of treatment – a median (95% CI)
increase of 3 (0, 4). Eleven patients showed an increase
of ≥3 points. There was no change in median (95% CI)
Figure 1 Patient disposition. *All enrolled population; ‡full analysis population; **all patients with at least one post-baseline liver assessment
(≥6 months) were included in primary endpoint analysis, including 11 patients who discontinued miglustat treatment prematurely; ††some
patients had more than one of the listed reasons for non-inclusion in the per-protocol analysis; ‡‡Patient had documented symptomatic bone
disease at screening and represented a protocol violation. Note: secondary efficacy evaluations based on full analysis population included
different numbers of patients subject to data availability.
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at the end of treatment compared with a median (95%
CI) increase of 3 (0, 7) among non-splenectomized
patients (n = 15). These results are consistent with an
increase in Gaucher cell infiltration in the bone marrow
in some of the splenectomized patients.
Plasma chitotriosidase activity determinations at base-
line and end of treatment were available for 28 patients.
Chitotriosidase activity showed marked inter-individual
variability at baseline, despite all patients having mild,
stable disease (range 17–5,863 nmoles/[mL*hr]). From a
baseline median (95% CI) value of 963 (420, 1,872)
nmoles/(mL*hr), there was a median (95% CI) increase
of 1,173 (643, 2,834) nmoles/(mL*hr) at end oftreatment. Analysis of changes in chitotriosidase activ-
ities between baseline and end of treatment for each
patient revealed a median (range) within-patient percent
change of +102% (−62% to 2334%).
A total of 20 cases were referred to the Steering Com-
mittee for adjudication of potential disease worsening,
including 11 patients referred during the study and 9
cases referred at the final end-of-study adjudication.
Thirteen patients were confirmed as having disease wor-
sening. For the remaining seven patients who were re-
ferred with one or more signals of possible worsening,
when considered alongside the overall clinical picture of
the patient, together with the clinical relevance of the
findings, the Steering Committee did not consider these
Table 2 Baseline and change from baseline in liver volume during up to 24 months of miglustat therapy (primary
analysis)
Non-splenectomized Splenectomized All
(N = 23) (N = 9) (N = 32)
Baseline absolute value (mL)
Mean ± SD 1742 ± 440 1857 ± 604 1775 ± 484
End of treatment absolute value (mL)
Mean ± SD 1736 ± 353 1704 ± 470 1727 ± 382
Absolute change from baseline (mL)
Mean −6.4 −152.6 −47.5
95% CI (−124, 111) (−395, 90) (−151, 56)
Percent change from baseline
Mean 1.3 −7.2 −1.1
95% CI (−4.6%, 7.3%) (−16.6%, 2.2%) (−6.0%, 3.9%)
Data analysis based on full analysis population.
Figure 2 Absolute changes in primary and secondary efficacy parameters during 24 months of miglustat therapy
(full analysis population). Changes from baseline in a) liver volume, b) spleen volume, c) hemoglobin concentration and d) platelet count. Data
are mean absolute change from baseline (square points), with 95% confidence intervals (grey boxes) and minimum–maximum value ranges
(solid vertical lines).
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Table 3 Individual patient data and primary and secondary efficacy parameter findings
Pt. # Gender Genotype Body wt. (kg) Tx duration (days) Liver (MN) Liver volume (mL) Spleen (MN) Spleen volume (mL) Hb (g/dL) Platelets
(x 109/l)
Chito nmol/
(mL*hr)
BL EOT BL EOT BL EOT BL EOT BL EOT BL EOT BL EOT BL EOT
1 M N370S/unknown 102 – 71 0.55 – 1420 – 3.40 – 696 – 15.1 – 127 – 159 –
2†,Ŧ M N370S/IVS 2 + 1 79.4 79.4 148 – 0.92 – 1833 – 5.52 – 876 15.4 15.6 93 95 781 1396
3† F R496H/G202R 59.8 57.4 734 1.05 0.94 1564 1345 SPX – SPX – 13.8 13.4 613 521 2915 1881
4† F N370S/L444P 126 86.8 716 0.64 0.87 1999 1890 SPX – SPX – 12.9 14.4 437 311 – 151
5†,Ŧ F N370S/unknown 69.7 62.8 408 0.85 0.85 1474 1333 2.66 3.54 371 445 14.0 12.1 233 148 974 3456
6 F N370S/L444P 86.3 – 75 0.73 – 1582 – 2.94 – 507 – 16.8 16.9 173 173 1165 –
7† M N370S/L444P 85.0 79.5 663 0.73 0.80 1545 1593 2.19 2.68 373 425 15.5 15.6 162 127 4729 1808
8†,Ŧ F N370S/EXG DEL G 48.0 46.0 245 1.49 1.54 1785 1774 SPX – SPX – 12.9 12.3 161 195 2887 5196
9† M N370S/L444P 91.0 85.0 732 0.98 0.89 2224 1891 9.90 10.4 1801 1761 14.3 14.0 100 98 1619 3139
10 M N370S/N370S 71.0 – 50 – – – – – – – – 15.3 – 139 – – –
11 M N370S/N370S 70.5 69.7 729 0.98 0.92 1729 1600 – 3.12 – 435 14.0 12.7 167 100 – 2156
12†,Ŧ F N370S/T134P 57.0 46.7 373 0.77 0.80 1100 935 SPX – SPX – 13.9 11.6 271 127 – 862
13 M N370S/N370S 76.3 – 3 0.94 – 1798 – 2.21 – 338 – 16.1 – 187 – 53 –
14†,Ŧ M N370S/K198E 70.1 70.1 190 1.04 1.11 1827 1938 2.72 3.51 382 492 15.2 12.2 160 150 – 4978
15†,Ŧ M N370S/84GG 83.6 75.3 515 1.49 1.20 3112 2258 4.66 3.77 779 568 13.3 12.4 199 149 – 20
16*,†,Ŧ M N370S/S107L 78.5 72.3 405 0.83 0.91 1627 1637 SPX – SPX – 13.4 11.6 283 188 420 3645
17 F N370S/D409H 81.2 – 109 1.02 – 2062 – 4.30 – 699 – 13.4 – 106 – 839 –
18*,† F N370S/L444P 59.2 57.4 741 1.33 1.19 1964 1715 2.91 3.11 344 357 13.5 12.1 177 99 1232 4113
19† M N370S/84GG 74.7 69.6 743 0.78 0.72 1463 1254 SPX – SPX – 17.0 13.1 225 155 1336 4200
20Ŧ F N37O/NK 51.5 – 112 1.04 – 1341 – 3.11 – 320 – 16.8 16.8 183 152 591 695
21† F N370S/N370S 73.5 69.0 729 0.66 0.67 1220 1148 1.44 1.29 211 179 13.8 13.3 160 153 80 41
22*,† F N370S/crossover 62.5 58.2 755 1.00 1.16 1562 1687 3.57 5.11 447 595 16.4 15.4 167 111 2326 2969
23† F N370S/unknown 82.5 68.5 718 0.93 1.00 1925 1706 5.03 6.40 830 877 16.6 16.1 104 91 389 4058
24† F N370S/N370S 67.7 65.9 740 0.82 0.86 1391 1416 2.00 1.80 270 238 16.4 14.6 226 191 27 17
25*,† M N370S/1327TT 72.0 72.0 754 1.22 1.22 2191 2204 4.51 6.23 650 897 15.0 14.8 152 79 2658 8348
26*,† F N370S/REC NEIL 61.0 51.0 732 0.95 1.06 1444 1349 1.61 2.84 197 289 14.8 13.4 186 113 666 3500
27*,†,Ŧ F N370S/L444P 55.9 56.8 478 1.12 1.25 1571 1770 4.01 5.08 449 577 13.6 10.8 148 99 1872 2897
28†,Ŧ M N370S/1035INSG 93.7 87.7 545 1.02 1.15 2391 2530 1.43 1.94 268 340 11.3 11.1 151 155 5863 6772
29*,† M ND 91.2 87.3 653 0.81 1.05 1847 2291 6.67 11.1 1217 1939 15.0 15.1 98 54 241 1703
30*,† M ND 86.1 84.8 765 0.81 0.97 1745 2063 2.40 4.07 413 690 16.8 14.7 158 116 3398 7138
31† M N370S/N370S 95.9 82.3 734 0.82 0.90 1964 1854 SPX – SPX – 14.8 14.4 264 251 – 110
32†,Ŧ M N370S/8499 71.2 79.8 239 0.92 0.75 1638 1496 2.18 2.18 311 348 14.9 14.1 186 128 391 590
33† F N370S/R257X 124 109 738 1.05 0.88 3274 2400 SPX – SPX – 17.8 13.9 229 219 44 1071
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Table 3 Individual patient data and primary and secondary efficacy parameter findings (Continued)
34*,† F N370S/unidentified 113 109 725 0.63 0.64 1788 1733 1.74 2.96 394 642 13.6 14.6 223 135 1587 4118
35*,† F N370S/unidentified 89.2 68.8 725 0.52 0.85 1152 1468 2.23 3.24 398 446 15.3 14.8 149 102 132 1002
36*,† M N370S/unidentified 70.3 68.9 725 0.97 1.09 1704 1880 2.94 4.34 413 598 14.2 14.6 177 158 13834
37Ŧ M N370S/unknown 76.0 – 140 0.75 – 1434 – 2.11 – 320 – 14.7 14.4 141 141 438 510
38*,† F 84GG/N370S 65.0 62.5 732 0.72 0.92 1162 1439 3.24 3.72 422 465 16.8 15.1 136 106 98 1271
39*,† M N370S/84GG 88.0 81.0 730 0.88 1.11 1932 2248 SPX – SPX – 17.1 14.8 254 174 1940 10636
40 M L444P/NA 54.4 – 22 0.81 – 1095 – 2.18 – 238 – 16.2 – 134 – – –
41 M N370S/N370S 76.7 – 15 0.80 – 1538 – 1.37 – 210 – 15.9 – 232 – – 38
42†,Ŧ F N370S/N370S 58.5 58.0 231 1.01 0.98 1471 1424 2.35 2.54 275 294 12.6 12.9 214 207 17 21
BL, baseline; Chito, chitotriosidase; EOT, end of treatment; Hb, hemoglobin; MN, multiples of normal; ND, not determined; SPX, splenectomy; Tx, treatment; WV, worst value. *Patients adjudicated as showing disease
worsening; †patients within therapeutic goals at baseline who were assessed for maintenance of therapeutic goals; Ŧpatients in whom therapeutic goals were adjudicated based on worst value (end-of-treatment)
analysis. Dashes represent patients in whom useable data values were not available or analyses (i.e. therapeutic goals) were not possible.
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http://www.ojrd.com/content/7/1/102particular signals sufficient to constitute disease worsen-
ing. On the basis of local assessment of organ volume,
two of these seven patients had been adjudicated as
worsened during the study; however, on the basis of
standardized central readings, they were not confirmed
as worsened at the end-of-study adjudication (patients 5
and 8 in Table 3).
Maintenance of therapeutic goals
Most patients in the full analysis population who were
within therapeutic goals for key type 1 Gaucher disease
parameters at baseline were maintained within goal up
to Month 24. Thirty-two patients had a baseline and a
post-baseline assessment for liver volume while on
miglustat therapy, and 29/32 (91%) who were within goal
at baseline remained within goal at Month 24. Of the
three patients who were outside the goal at baseline, two
were within the goal and one remained outside goal by
the end of treatment. For other parameters, the numbers
and proportions of patients with available data who were
within goal at baseline and remained within goal at the
end of treatment were: 20/21 (95%) for spleen volume;
33/35 (94%) for hemoglobin concentration; 29/34 (85%)
for platelet count. Overall, 21/25 (84%) evaluable
patients showed maintenance of disease stability across
all disease parameters between baseline and the end of
treatment.
Safety and tolerability
Safety and tolerability assessments did not reveal any
new or unexpected safety findings, and were consistent
with the known safety profile for miglustat [11]. Gastro-
intestinal disorders were the most frequently reported
adverse events among the all-enrolled population, with
diarrhea, flatulence and abdominal discomfort reported
most frequently (Table 4). Eleven out of 41 patientsTable 4 Treatment-emergent adverse events* during 24
months of miglustat therapy (all-enrolled population)
Adverse event Incidence (N = 42)
n %
Diarrhea 31 31 (74)
Flatulence 21 21 (50)
Tremor 15 15 (36)
Headache 9 9 (21)
Paresthesia 9 9 (21)
Fatigue 8 8 (19)
Dizziness 7 7 (17)
Arthralgia 6 6 (14)
Weight decreased 6 6 (14)
Abdominal discomfort 5 5 (12)
Hypoesthesia 5 5 (12)
*Adverse events with ≥10% incidence.(27%) in the full analysis population commenced as-
needed treatment with loperamide for gastrointestinal
disturbances during miglustat therapy.
Body weight decrease was reported as an adverse event
in 6/42 (14.2%) patients, among whom 5 cases were con-
sidered related to miglustat therapy. The mean (SD) de-
crease in body weight among all patients between
baseline and Month 24 was –7.7 (9.1) kg; median (range)
decrease –4.6 (−39.0–0) kg.
Doses of miglustat were reduced from 100 mg t.i.d. to
100 mg b.i.d. in a total of three patients due to adverse
events: two were due to gastrointestinal disturbances
and one was due to cerebellar syndrome and hyper-
reflexia. Two of these patients later discontinued miglu-
stat treatment prematurely, and their adverse events
resolved with no clinical sequelae. One patient (with
dose reduction due to diarrhea) went on to complete the
study.
Thirteen out of 42 (31%) patients in the all-enrolled
population discontinued miglustat therapy on account of
adverse events that did not indicate worsening of
their disease. Diarrhea and tremor were associated
with discontinuations in 7/42 (17%) and 3/42 (7%)
patients, respectively. Abdominal discomfort and abdom-
inal distension were associated with discontinuations in 1
patient each. Most discontinuations related to adverse
events occurred early during miglustat therapy: eight
patients discontinued miglustat before Month 6, and two
others between Months 6 and 12.
A further 5/42 (11.9%) patients discontinued miglustat
therapy prematurely due to adverse events that may have
been indicative of disease worsening according to
protocol-defined criteria. These included increased chit-
otriosidase activity, decreased platelet count, decreased
hemoglobin and splenomegaly. The reason for early dis-
continuation of miglustat therapy in these patients was
recorded as ‘disease worsening’ in accordance with the
study protocol in order to differentiate discontinuations
due to tolerability issues from those required by the
disease worsening criteria (see Secondary efficacy sec-
tion); one patient was discontinued due to ‘disease wor-
sening’ criteria without any corresponding adverse event
being recorded.
All 42 patients had a baseline electrodiagnostic assess-
ment, among whom three (7.1%) were diagnosed with
mononeuropathy. Seven (16.7%) had minor electrodiag-
nostic abnormalities without clinical evidence of periph-
eral neuropathy, and five (12%) had electrodiagnostic
abnormalities compatible with peripheral neuropathy.
During the study, one of the seven patients with minor
electrodiagnostic abnormalities but no clinical signs or
symptoms of peripheral neuropathy at baseline devel-
oped a mild sensorimotor neuropathy that was not
attributed to the study medication. This patient was
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and miglustat was continued without ill effect.
Neuropsychological investigations indicated no signs
of cognitive deterioration associated with miglustat
treatment. There was no consistent or progressive de-
cline among the various neurocognitive tests.
Discussion
Oral treatment with miglustat for 24 months prevented
pathological storage in liver as evidenced by the main-
tenance of liver size. The mean percent change in liver
volume from baseline during 24 months of miglustat
therapy (−1.1) was well within the pre-defined non-infer-
iority limit of 10%, and thus the primary efficacy end-
point of this 24-month, open-label non-inferiority study
was met. In addition, all patients who were within the
proposed therapeutic goal for liver volume at baseline
were maintained within this goal throughout the study
[21]. Liver volume was therefore maintained in patients
with stable type 1 Gaucher disease who changed to
miglustat after previous long-term enzyme therapy.
Change in liver volume has been recommended as a
consistent clinical indicator of disease course and treat-
ment effects in type 1 Gaucher disease as it does not
tend to show the degree of inter-patient variability seen
with other key disease parameters [28]. Liver volume or
ratio has been assessed as the primary efficacy endpoint
in a number of previous clinical trials alone or in com-
bination with spleen volume [15,19,29], and was chosen
following detailed discussions with the EMA at the time
of trial design. Moreover, the analytical approach
adopted in this study allowed an objective, quantitative
assessment of this endpoint.
Inclusion of a placebo arm was considered unethical
and impracticable in this treatment and patient setting,
which is unfortunate as the absence of a suitable control
group prevents a robust evaluation of the effects of
miglustat in patients who have already had the benefit of
enzyme therapy. Previous data indicate that a 2-year
treatment interruption would carry a risk of recurrent
clinical disease in some patients, accompanied by severe
fatigue and reappearance of bone pain and other skeletal
manifestations of untreated Gaucher disease [10,30-33].
Exploratory analysis of the key secondary efficacy end-
points (spleen volume, hemoglobin concentration and
platelet count) were included in the trial design after the
primary endpoint was agreed with the EMA, based on
their scientific relevance. Overall, these secondary end-
points indicated stable disease between baseline and the
end of miglustat treatment. High proportions of patients
who were within therapeutic goals for each parameter at
baseline were maintained within goal up to Month 24.
The clinical relevance of the absolute mean changes in
secondary efficacy parameters, most of them in thedirection of disease progression, is difficult to interpret.
The mild baseline disease burden of the study population
should be taken into account. For instance, the 102 mL
increase in spleen volume in non-splenectomized patients
at end of treatment should be considered in the context of
the low mean absolute baseline value of 510 mL, com-
pared with values normally seen in long-term enzyme
therapy patients. In all, 8/30 (27%) patients showed clinic-
ally relevant increases in spleen volume.
Small mean absolute reductions in hemoglobin were
observed during miglustat therapy(−0.95 g/dL from a
baseline of 14.8 g/dL). Four out of 41 (10%) patients had
clinically relevant decreases in hemoglobin indicative of
disease progression but, as with the organ volume find-
ings, the great majority (94%) of patients was maintained
within the normal range. The proportion of patients
remaining stable for platelet count (85%) from baseline
to Month 24 was slightly lower than for other key para-
meters, with an absolute mean change of −44.1 × 109/L.
Nine of 41 (22%) patients had decreased platelet counts
that were considered potentially relevant.
The relevance of plasma chitotriosidase for monitoring
disease status in patients with stable, mild type 1 Gau-
cher disease after switching to miglustat in relation to
prognosis is currently unclear. Consistent with other sys-
temic disease parameters, the median absolute chitotrio-
sidase activity was low at baseline (963 nmoles/[mL*hr])
but was variable between patients despite long-term
enzyme therapy. Changes in chitotriosidase activity in
response to miglustat treatment were also highly vari-
able, with some patients showing marked increases; this
suggests that these patients had ‘subclinical’ disease pro-
gression, which was unassociated with clinical events.
Miglustat has been shown to significantly reduce plasma
chitotriosidase activity in treatment-naïve patients over 3
years of therapy [13,14]. In the previous open-label ran-
domized study reported by Elstein et al. [19], mean
chitotriosidase activity remained stable during miglustat
therapy in 27/28 (96%) patients with type 1 Gaucher dis-
ease after switching from long-term enzyme therapy.
Similar findings were reported in the Spanish ZAGAL
cohort study [16].
Bone pain (rated on a visual analogue scale ranging
from 0 to 100) was unchanged during 24 months of
miglustat treatment, and none of the 17 evaluable
patients who were free of bone pain at baseline experi-
enced pain episodes throughout follow up. MRI-based
BMB scores indicated a slight increase in bone marrow
infiltration over 24 months. Again, this may indicate
subclinical disease progression in some patients. Of note,
there was no median change in BMB score among the
six splenectomized patients, compared with the small
median change (+3) among the 15 patients with intact
spleens. Previously, stable BMB scores have been
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enzyme therapy to miglustat [34]. Long-term follow up
in a Spanish cohort of switch patients showed an im-
provement in lumbar spine bone marrow infiltration
during 48 months of therapy [16].
It is not possible to discern whether patient genotype
had an influence on the changes in these disease para-
meters, due to the small sample size. From the genotype
data presented in Table 3 there does not appear to be any
clear association of a particular genotype with disease wor-
sening or improvement during miglustat therapy.
To ensure the safety of patients who might show de-
terioration, we used conservative exploratory criteria to
identify patients with ‘suspected disease worsening’ after
switching from a stable dose of enzyme therapy to
miglustat. These criteria do not reflect those generally
used in clinical practice [35]. Based on the criteria
defined in the trial protocol, miglustat treatment was
discontinued in a total of six patients, as adjudicated by
the Steering Committee. The number of patients finally
adjudicated as exhibiting disease worsening (n = 13) was
lower than the total number of cases with suspected dis-
ease worsening referred by investigators during or at the
end of the study (n = 20). This may be related to the fact
that decision making regarding disease worsening during
the study was based on local readings, while the Steering
Committee utilized both local readings and standardized
central readings at the end of the study.
No new or unexpected safety findings came to light
during this 24-month study and, overall, the safety and
tolerability of miglustat was found to be consistent with
its known safety profile [11,13-15,19,36]. Gastrointestinal
effects such as diarrhea and flatulence were the most
frequently reported adverse events, and were the most
frequent reason for premature discontinuation of ther-
apy. In this respect, it is regrettable that firm guidance
for avoiding or ameliorating gastrointestinal distur-
bances, such as dietary modification in the early phase
of treatment, was not specified in the study protocol.
Such interventions during the initial weeks of miglustat
therapy can substantially improve tolerability [37,38].
Notably, patients attending the one center where indi-
vidual dietary guidance was provided reported the least
severe gastrointestinal side effects.
No new cases of peripheral neuropathy with clinical
symptoms attributable to miglustat occurred in the
present study. The observed 11.9% prevalence of neur-
opathy at baseline is in agreement with the prevalence of
peripheral neuropathy (11%) reported in a previous
study of 103 type 1 Gaucher disease patients not receiv-
ing this agent [4]. Findings from the neuropsychological
assessments conducted in this study were in line with
data from the miglustat post-marketing surveillance pro-
gram [36].To an extent, the current study allows a limited inter-
pretation of the therapeutic role of miglustat in Gaucher
disease. The wide variability in response between
patients included in this study, alongside the appreciable
rate of premature discontinuations from therapy, suggest
that the use of miglustat as a maintenance therapy in
GD1 might be suitable for a distinct group of patients.
However, additional data would be required to fully de-
fine such a group.
With regard to the higher than expected patient drop-
out from this study, it seems likely that the stringent cri-
teria we adopted to define ‘disease worsening’ may have
contributed to their withdrawal. However, we defend the
rigorous adjudication process because of the need to en-
sure that no patient experienced unnecessary or unto-
ward deterioration during the protracted (2-year) course
of the trial. The criteria that were adopted for withdraw-
ing patients from this study do not reflect those that are
used in therapeutic decision-making regarding treatment
failure in clinical practice. Finally, while an examination
of the achievement of therapeutic goals was included in
the statistical analysis plan, it was not defined a priori,
and thus should be interpreted with caution. In addition,
such an analysis may lack sensitivity, as it is possible that
patients experiencing deterioration in a particular dis-
ease parameter could still remain within the range for
the goal.
Conclusions
The primary efficacy endpoint was met; overall there
was no change in liver volume during 24 months of
miglustat therapy. However, a notable proportion of
patients showed a gradual deterioration in some disease
manifestations, suggesting that miglustat could maintain
clinical stability, but not in all patients. Miglustat
demonstrated a predictable profile of safety and toler-
ability that was consistent with that reported in previous
clinical trials and experience in clinical practice. Gastro-
intestinal tolerability was identified as an important
clinical management issue in this study and should be
actively addressed, particularly during the early weeks of
miglustat therapy.
Appendix
Miglustat Maintenance Study Group investigators and
patient numbers per center: Amato D, Toronto, Canada
(n = 5); Belmatoug N, Paris, France (n = 1); Cox TM,
Cambridge, UK (n = 6); Fernhoff P, Decatur, USA
(n = 3); Giraldo P, Zaragoza, Spain (n = 2); Giugliani R,
Porto Alegre, Brazil (n = 1); Hollak CEM, Amsterdam,
the Netherlands (n = 3); Hwu W-L, Taipei, Taiwan
(n = 1); Malinová V, Prague, Czech Republic (n = 2);
Packman S, San Francisco, USA (n = 1); Pastores G,
New York, USA (n = 3); Rhead WJ, Wauwatosa, USA
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http://www.ojrd.com/content/7/1/102(n = 3); Rowell J, Herston, Australia (n = 1); Steiner RD,
Oregon, USA (n = 6); Szer J, Carlton, Australia (n = 2);
Tifft-Rosenbaum K, Washington DC, USA (n = 2).
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